Artificial intelligence (AI) can match physician insulin dosing, maintaining target blood sugar levels in patients with type 2 diabetes. A study showed an AI-based insulin decision support system's ...

The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can ...

Glooko’s software already gives people with diabetes a single place to pool all of the data from their health-tracking devices, and, now, it’s taking a more active role in helping manage their ...

Adults with type 1 diabetes had an increase in total daily insulin dose and bolus insulin dose shortly after stopping ...

The move was cheered by a packed room of diabetes patients, parents, advocates, and doctors. Some see the change as a first step toward getting Medicare to cover CGM. After hearing from supporters ...

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 In the trial, efsitora met the primary ...

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to ...

NovoLog (insulin aspart) is a prescription medication used to manage blood sugar levels in people with type 1 or type 2 diabetes. NovoLog dosage varies based on individual factors such as the type of ...

Dr. Yuanjie Mao has led a study published in the Journal of the American Medical Association (JAMA) Oncology looking at the correlation between daily insulin dose and cancer incidence (the number of ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...